Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.

Sci Rep · 2021 · PMC8664812 · PMID 34893673

Europe PMC DOI

hedged sentence

0.1540

closest p · 3.1× alpha

0.1540

boldest claim

The sentences

showed a trendp = 0.154not close (p > 0.1)

Patients with high plasma AREG levels also showed a trend toward inferior OS (33.0 months [95% CI 0.0–66.1 months] vs. not reached, respectively; p = 0.154) (Fig. 1 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.